Skip to main content
curacle co., ltd. logo

curacle co., ltd. — Investor Relations & Filings

Ticker · 365270 ISIN · KR7365270008 KO Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2022-02-14 Regulatory Filings
Country KR South Korea
Listing KO 365270

About curacle co., ltd.

http://www.curacle.com/eng/main/

Curacle Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative drugs for intractable vascular diseases. The company's core platform technology centers on developing highly effective protectors against endothelial dysfunction, a key factor in various age-related and vascular conditions. Its development pipeline includes novel treatments targeting significant unmet medical needs, with a particular focus on conditions such as Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration (wet AMD), diabetes, and stroke. Curacle aims to create differentiated therapies through innovative targets and treatment concepts, including the development of orally administered medications for complex eye diseases.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최
Regulatory Filings Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as date, location, purpose, and where the presentation materials will be available. Since it is an announcement of an event and the availability of materials rather than the presentation itself, and it fits the regulatory announcement format for corporate events, it is classified as a Regulatory Filing (RNS).
2022-02-14 Korean
투자판단관련주요경영사항(습성 연령관련 황반변성의 경구용 치료제 CU03-1001 임상 2a상 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Curacle) regarding the results of a Phase 2a clinical trial. It follows the standard format for 'Major Management Matters' (주요경영사항) filings in the Korean market, which are used to disclose material information such as clinical trial outcomes. Since it provides detailed clinical data, safety profiles, and efficacy results rather than just announcing the existence of a report, it falls under the category of regulatory filings for material corporate events.
2022-01-10 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 100% confidence The document is a 'Report on the Completion of Merger, etc.' (합병등종료보고서) filed with the Financial Supervisory Service of South Korea. It details the finalization of a tangible asset acquisition (real estate) by Curacle Co., Ltd. Since this document reports the completion of a specific corporate transaction (asset acquisition) rather than a general regulatory announcement or a report publication notice, it falls under the category of M&A Activity (TAR), which covers mergers, acquisitions, and significant asset transfers.
2021-12-29 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (the 6th Annual General Meeting). It does not contain the full proxy materials or the meeting presentation itself, but rather serves as a formal notice of the record date for shareholder rights. Given its nature as a regulatory notification of a corporate event, it falls under the general regulatory filing category.
2021-12-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. It details changes in share ownership by major shareholders and special related parties, specifically due to the exercise of stock options. This type of filing is a standard regulatory disclosure for significant changes in shareholding, which falls under the 'Major Shareholding Notification' category.
2021-12-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often referred to as a 'Director's Dealing' or 'Insider Trading' report) where company insiders report changes in their shareholdings, including stock options and equity ownership. This fits the 'Director's Dealing' (DIRS) category perfectly.
2021-12-13 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.